Home Behandelprotocollen PMF Richtlijnen en literatuur

Richtlijnen


Klik HIER voor de behandelrichtlijn PMF (2018) van de HOVON werkgroep CML - MPN.

Literatuur  

  1. DA Arber et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 127:2391-2405
  2. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues – International agency for research on cancer, Lyon 2017.
  3. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon 2008, 44-47
  4. Cervantes F et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113(13):2895-901
  5. Gangat N et al. DIPSS-Plus: a refined Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 2011;29(4):392-397.
  6. Landolfi R et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350(2): 114-24
  7. Harrison CN et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353(1): 33-45.
  8. Verstovsek S et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis N Engl J Med 2012; 366:799-807
  9. Harrison C et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis N Engl J Med 2012; 366:787-798 8. Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy
  10. Dupriez et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013; 162(2):783-91
  11. Mesa RA et al. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leuk Lymphoma 2001; 42(5): 901-11
  12. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009;113(22):5394-400
  13. Elliott MA et al. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103(2):505-11
  14. Petti MC et al. Br J Haematol. 2002;116(3):576-81
  15. Kerbauy DM et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13(3): 355-65
  16. Cervantes F et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127(4): 399-403
  17. Cervantes F et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129(6):771-5
  18. Shimoda K et al.  The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol. 2007; 85(4): 338-43
  19. Mesa RA et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101(7): 2534-41
  20. Abgrall JF et al. Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS). Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica. 2006; 91(8): 1027-32
  21. N. Holle et al. Thalidomide and lenalidomide in primary myelofibrosis. Neth J Med 2010, 68(6/7): 293-98
  22. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-69
  23. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103
  24. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018 May;32(5):1057-69
  25. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011 Feb 1;29(4):392-7
  26. Guglielmelli P, Lasho TL, Rotunno G et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients with Primary Myelofibrosis. J Clin Oncol. 2018 1;36(4):310-31
  27. Hernández-Boluda JC, Pereira A, Correa JG, et al. Prognostic risk models for transplant decision-making in myelofibrosis. Ann Hematol. 2018 May;97(5):813-20
  28. Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012 Oct;130 Suppl 1:S1-3
  29. Kröger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015 125;3347-50

Ga terug naar de PMF homepage of lees meer over PMF: Ga terug naar de algemene homepage Behandelprotocollen.